Odborný přehled — medicínský obsah: Bispecific 10E8 4 iMab broadly neutralizing antibody in people with or without HIV 1 a partially ra

Nature Medicine, Published online: 07 July 2026; doi:10.1038/s41591-026-04472-w A first-in-human. partially randomized and placebo-controlled phase I trial examined the safety, tolerability. pharmacokinetics and antiviral activity of the bispecific 10E8.4/iMab broadly neutralizing monoclonal antibody in people living with or without HIV. and found it was safe and well tolerated at different dose l.

Co funguje v praxi